ATE396737T1 - Prophylaxe, behandlung und prognose/überwachung von sepsis und septischem schock - Google Patents

Prophylaxe, behandlung und prognose/überwachung von sepsis und septischem schock

Info

Publication number
ATE396737T1
ATE396737T1 AT03741651T AT03741651T ATE396737T1 AT E396737 T1 ATE396737 T1 AT E396737T1 AT 03741651 T AT03741651 T AT 03741651T AT 03741651 T AT03741651 T AT 03741651T AT E396737 T1 ATE396737 T1 AT E396737T1
Authority
AT
Austria
Prior art keywords
sepsis
apoci
prognosis
monitoring
treatment
Prior art date
Application number
AT03741651T
Other languages
English (en)
Inventor
Patrick Rensen
Aloysius Havekes
Original Assignee
Tno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tno filed Critical Tno
Application granted granted Critical
Publication of ATE396737T1 publication Critical patent/ATE396737T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT03741651T 2002-06-28 2003-06-27 Prophylaxe, behandlung und prognose/überwachung von sepsis und septischem schock ATE396737T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL1020962A NL1020962C2 (nl) 2002-06-28 2002-06-28 Therapie en prognose/monitoring bij sepsis en septische shock.

Publications (1)

Publication Number Publication Date
ATE396737T1 true ATE396737T1 (de) 2008-06-15

Family

ID=29997579

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03741651T ATE396737T1 (de) 2002-06-28 2003-06-27 Prophylaxe, behandlung und prognose/überwachung von sepsis und septischem schock

Country Status (8)

Country Link
US (2) US9176153B2 (de)
EP (1) EP1517696B1 (de)
JP (1) JP5093830B2 (de)
AT (1) ATE396737T1 (de)
AU (1) AU2003280523A1 (de)
DE (1) DE60321341D1 (de)
NL (1) NL1020962C2 (de)
WO (1) WO2004002518A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044554A2 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
DE10343815A1 (de) * 2003-09-22 2005-04-14 B.R.A.H.M.S Ag Verfahren zur Diagnose von Erkrankungen unter Bestimmung von Apolipoprotein C-I, und dessen Verwendung in der Therapie von Erkrankungen
EP2376923A4 (de) * 2008-12-22 2012-08-15 Children S Res Inst Verfahren für den nachweis von sepsis
CA2799536C (en) * 2010-06-03 2020-03-10 Idexx Laboratories, Inc. Markers for renal disease
CN105652019B (zh) * 2016-02-22 2017-10-20 西安交通大学 一种孤独症血清多肽标志物apoc1‑a及其应用
AR107786A1 (es) 2016-03-02 2018-06-06 Idexx Lab Inc Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
US20220334127A1 (en) * 2019-03-13 2022-10-20 Fundación Para La Formación E Investigación Sanitarias De La Región De Murcia (Ffis) In vitro method for obtaining clinical data in patients suffering from an inflammatory disease
CN111208305B (zh) * 2020-02-16 2023-04-25 重庆翼锋生物科技有限公司 Hbp和pct在败血症诊断试剂制备中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594113A (en) * 1988-06-23 1997-01-14 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
IL131118A0 (en) * 1999-07-26 2001-01-28 Trellis Photonics Ltd Electroholographic wavelength selective photonic switch for wdm routing

Also Published As

Publication number Publication date
JP5093830B2 (ja) 2012-12-12
US20060111283A1 (en) 2006-05-25
US20160030516A1 (en) 2016-02-04
JP2005537243A (ja) 2005-12-08
WO2004002518A1 (en) 2004-01-08
NL1020962C2 (nl) 2003-12-30
DE60321341D1 (de) 2008-07-10
US9176153B2 (en) 2015-11-03
AU2003280523A1 (en) 2004-01-19
EP1517696B1 (de) 2008-05-28
EP1517696A1 (de) 2005-03-30

Similar Documents

Publication Publication Date Title
Bennick et al. The role of human salivary acidic proline-rich proteins in the formation of acquired dental pellicle in vivo and their fate after adsorption to the human enamel surface
McMullen et al. Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains
ATE327764T1 (de) Hmg1 antagonisten zur behandlung von entzündungen
Campese et al. Concentration and fate of histatins and acidic proline-rich proteins in the oral environment
DE60009896T2 (de) Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten
JP2022126766A (ja) 活性薬剤の経口投与のための製剤
DE60321341D1 (de) Prophylaxe, behandlung und prognose/überwachung von sepsis und septischem schock
HUP0401501A2 (hu) Érrendszeri gyulladás kezelése vagy megelőzése szterin-felszívódást gátló anyagokat tartalmazó gyógyszerkészítmények alkalmazásával
DK1401422T3 (da) Halogenholdig sammensætning, fremgangsmåde til fremstilling heraf og anvendelser heraf
Jainkittivong et al. The relationship between salivary histatin levels and oral yeast carriage
Fujimoto et al. The wound/burn guidelines–4: Guidelines for the management of skin ulcers associated with connective tissue disease/vasculitis
BR9808804A (pt) Processos para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior incluindo o esÈfago e o estÈmago, para tratar um indivìduo para proliferar o tecido do trato gastrointestinal superior, para identificar peptìdeos utilizável para tratar condições inflamatórias, para identificar peptìdeos, utilizável para evitar ou melhorar as condições inflamatórias, utilizável para identificar peptìdeos capazes de proliferar tecido do trato gastrointestinal superior, para tratar profilaticamente um indivìduo, para melhorar o crescimento do tecido do trato gastrointestinal superior em um mamìfero, e para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior, kit, processos para promover o crescimento de tecido do trato gastrointestinal superior ou células, para tratar um paciente para restaurar o trato gastrointestinal superior, para determinar a atividade de um hormÈnio quando usado em combinação com glp-2, para tratar um indivìduo tendo úlceras peptìdicas
Laurberg Tranexamic acid (Cyklokapron) in chronic urticaria: a double-blind study
Taira et al. Statherin-derived peptide protects against intrinsic erosion
FR2861731B1 (fr) Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
WO2003035679A3 (en) Molecules
Lee et al. Snake venom proteomics and antivenomics of two Sundaic lance-headed pit vipers: Trimeresurus wiroti (Malaysia) and Trimeresurus puniceus (Indonesia)
Aguirre et al. Levels of salivary cystatins in periodontally healthy and diseased older adults
BRPI0413404A (pt) composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif
Bee et al. Novel in vitro assays for assessing the haemorrhagic activity of snake venoms and for demonstration of venom metalloproteinase inhibitors
Leslie et al. Absence of blood-pressure lowering effect of captopril in anephric patients.
ATE405649T1 (de) Hemmstoff zur diagnose und behandlung von haemophilia a patienten
Rikimaru et al. Relationship between endothelin-1 and interleukin-1β in inflamed periodontal tissues
Ferguson et al. Investigation of coagulopathy in three cases of tiger snake (Notechis ater occidentalis) envenomation
Dubljanin-Raspopović et al. Is anemia at admission related to short-term outcomes of elderly hip fracture patients?

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1517696

Country of ref document: EP